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ABSTRACT 
Background and Objectives: Pneumonia with Acinetobacter baumannii has a major therapeutic problem in health 
care settings. Decision to initiate correct antibiotic therapy requires rapid identification and quantification of organism. 
The aim of this study was to develop a rapid and sensitive method for direct detection of A. baumannii from respiratory 
specimens. 
Materials and Methods: A Taqman real time PCR based on the sequence of blaoxa-51 was designed and used for direct 
detection of A. baumannii from 361 respiratory specimens of patients with pneumonia. All specimens were checked by 
conventional bacteriology in parallel. 
Results: The new real time PCR could detect less than 200 cfu per ml of bacteria in specimens. There was agreement 
between the results of real time PCR and culture (Kappa value 1.0, p value < 0.001). The sensitivity, specificity and 
predictive values of real time PCR were 100%. The prevalence of A. baumannii in pneumonia patients was 10.53 % (n = 38). 
Poly-microbial infections were detected in 65.71% of specimens.
Conclusion: Acinetobacter baumannii is the third causative agent in nosocomial pneumonia after Pseudomonas 
aeroginosa (16%) and Staphylococcus aureus (13%) at Tehran hospitals. We recommend that 104 CFU be the threshold 
for definition of infection with A. baumannii using real time PCR.
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INTRODUCTION
Strains of Acinetobacter baumannii have emerged 
as causative of nosocomial infections, posing high 
morbidity and mortality at hospitals throughout 
the world (1). The organism has also recently been 
isolated from cases with community acquired 
pneumonia (CAP) (2). Although the virulence factors 
of Acinetobacter have not been fully determined, (2- 
4), it has been identified as one of the three greatest 
threats to admitted patients at hospitals (1). The 
organism is able to rapidly develop resistance to all 
recommended antibiotics far exceeding P. aeroginosa 
capabilities (5).
Successful treatment of nosocomial pneumonia 
resulting from this “very successful pathogen” 
(3) requires detection of A. baumannii in clinical 
specimens (1, 6, 7). The guidelines of the American 
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(ATS/IDSA) recommend empirical therapy for 
pneumonia at admission only, and the microbiologic 
detection of pathogens should be initiated as soon as 
possible. Besides accurate detection, quantification 
of A. baumannii particularly in pneumonic samples 
for effective, timely, and accurate therapy is critical 
(8). This is the reason why the guidelines for hospital 
associated pneumonia (HAP) and ventilator associated 
pneumonia (VAP) patients try to prevent inappropriate 
and overuse of prescription antibiotics. In presence 
of pneumonia symptoms (body temperature > 38°C, 
leukocytosis or leukopenia and purulent exudate) and 
detection of causative agent, empirical therapy can be 
initiated (ATS/IDSA guideline) (8, 9). Differentiation 
of colonization from true pneumonia in hospitalized 
patients is difficult. However, isolation of 104cfu/ml 
from clinical respiratory specimens has been defined 
as a cut-off for infection (2). Despite this definition, 
literature is scarce and there is controversy concerning 
the method for determination of A. baumannii 
threshold when the physicians perform pathogen-
directed therapy. Conventional bacteriology for 
detection and quantification of A. baumannnii is time 
consuming and its sensitivity is lower than molecular 
techniques such as real-time PCR; therefore, real time 
PCR can also be regarded as more cost-effective. Data 
concerning rapid diagnosis of A. baumannii directly 
from clinical specimens in particular respiratory 
specimens is rare. Real-time PCR can overcome this 
problem since it quantitatively detects A. baumannii 
from pneumonic patients (10, 11). The technique 
takes less than two hours and produces results with 
high sensitivity and specificity. We have previously 
found that different clones of A. baumannii with 
multi-drug resistant (MDR) and pan-drug resistant 
(PDR) phenotypes exist at Tehran Hospitals (12).  In 
this study, we designed a TaqMan-based real-time 
PCR assay for rapid detection and quantification 
of A. baumannii from the respiratory specimens of 
patients with pneumonia and compared the results 
with those obtained by conventional bacteriology. 
To our knowledge, this is the first study conducted 
in the Middle East in which a molecular technique 
was used to differentiate colonization from infection 
by introducing a cut-off that detects infections by A. 
baumannii in hospitalized patients.
MATeRIALS AND MeTHODS
Clinical specimens and isolates. A total of 361 
clinical specimens including bronco alveolar lavage 
(BAL), sputum, tracheal aspirates and throat swabs 
were collected from 2 teaching and 2 private hospitals 
of Tehran, Iran (Table 1). The BAL and tracheal 
aspirate specimens (218 of BAL and 86 tracheal 
aspirates) were collected from patients at ICU or 
RCU, of which 80 were collected from patients with 
ventilated associated pneumonia (VAP). Sputum and 
throat swab specimens occupied 57 total specimens, 
of which 45 were taken at emergency units during 
January 2009- February 2010. Hospital associated 
pneumonia was diagnosed based on the ATS/ IDSA 
guideline (9) i.e., pneumonia was detected by 
infiltration on chest x-ray, clinical findings (body 
temperature more than 38.5 or less than 36°C 
and leukocytosis or leukopenia) and patients who 
developed a new pneumonia infection on mechanical 
ventilation for more than 96 hours, diagnosed as 
having VAP (13).  Information concerning the age, 
symptoms and underlying diseases of patients with 
pneumonias in this study is shown in Table 2.   
From every BAL or sputum specimens, 2 ml was kept 
at -20°C for real time PCR and Swab of patient was 
suspended in a tube containing two milliliter of 0.85% 
NaCl, and the remainder was used for bacterial culture 
and identification using standard methods as described 
previously. In brief, a calibrated loop (0.01μl) was used 
to streak the specimens on the plates containing blood 
agar and the colonies were counted after overnight 
incubation (14). Identification of isolates as A. baumannii 
was based on Gram staining, colonial morphology and 
biochemical properties (14). Culture and counting of the 
resulted colonies were done in duplicate. Count report-
ing for culture based on Colony Forming Unit (CFUs) 
were 1,000–10,000–50,000 and 100,000 (14, 15).
DNA extraction: DNA was extracted using 
enzyme digestion and the phenol chloroform method 
as described previously (16). Five microliter aliquots 
of extracted DNA solution were used as template in 
Real Time PCR assay (16). 
Standards, sensitivity and specificity: A. 
baumannii (NCTC 19606) and human DNA were 
used as positive and negative controls respectively. 
From the overnight growths of A. baumannii, serial 
dilutions containing 102 CFU/ml to 108 CFU /ml were 
prepared in 0.85% NaCl. They were used for drawing 
standard curve and to determine the sensitivity 
of real time PCR by comparing Standard tube to 
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turbidity of 0.5 McFarland (approximate count 1.5×108 
CFU/ml bacteria) and using spectrophotometer 
(Eppendorf, Hamburg, Germany) as described 
previously (16). When culture-based colony count 
and spectrophotometry differences were < 1%, it 
was considered as standard tube (It had calculated 
colony forming unit/ ml). DNA was extracted from 
200μl of the standard tubes and specimens (16).
Bacterial DNA from Pseudomonas aeruginosa 
(ATCC 49189) Stenotrophomonas maltophilia 
(NCTC10257), Klebsiella pneumoniae (NCTC 5056), 
Escherichia coli (NCTC 21157), Staphylococcus 
aureus (ATCC 29213), Streptococcus pneumoniae 
(NCTC11910), Legionella pneumophila (NCTC 
11192), Mycoplasma pneumoniae, (NCTC 10119) 
and human DNA were used as negative controls in 
real time PCR. Beta actin gene (primer and probe) 
was used as internal control with every sample to 
detect PCR inhibitor as recommended (17). The 
human white blood cell DNA was used as negative 
control in this study since our primers and probe do 
not react with human genome.
The specificity of the developed Real Time PCR 
was assessed using the above standard bacterial 
strains as well as the specimens that were positive for 
other microorganisms. For plotting standard curve, 
Real Time PCR assays were performed in duplicate.
primer design. bla oxa-51 gene sequence which is 
specific to A. baumannii, was selected based on our 
previous study (12). Conserved sites were identified 
by multiple alignments in NCBI and a primer pair and 
probe were designed using primer 3 plus (http://www.
bioinformatics.nl/cgi-bin/primer3plus/primer3plus.
cgi). The specificity of the candidate primers and 
probe for all bacterial sequences in the database were 
verified by FASTA analysis. (http://www.ncbi.nlm.
nih.gov/GenBank)
For amplification of the blaOXA-51, forward primer: 
Oxa51-F: 5-CTCGTGCTTCGACCGAGTAT-3, 
reverse primer: Oxa51-R: 
5 - A A C C A A C A C G C T T C A C T T C C - 3 
(20bp) and probe: Oxa_ probe: 5- Texas Red 
–ATGAAAGCTTCCGCTATTCCGGTT-BHQ3-3 
(24bp, Tm = 66) were designed. The size of 
amplicon was 247bp. 
Real-time pCR. Amplification and detection were 
performed in LinGene K Real Time PCR apparatus 
(Bioer, Hangzhou, P.R. China). The reactions 
consisted of 0.2 μM of each primer and probe, 0.2 
μM dNTP, 1.5μM MgCl2, 1.2U of DNA polymerase 
(mi Taq- Metabion, Martinsried, Germany), 5μ of 
10x PCR buffer, and 5 μl of the template DNA in 
total volume of 45μl with double distilled water. The 
Table 1. Number of Clinical specimens and isolates.
Specimens BAL Tracheal aspirate Sputum & swab
 HAP 201 21 12
VAP 17 63 0
CAP 0 2 45
Total 218 86 57
Characteristic HAp (%) VAp (%) CAp (%)
Age (Mean) 35-78 (56.4 ± 2.3) 14-68 (58.3 ± 2.9) 8-59 (39 ± 1.1)
Body temperature ≥ 38.5ºC 234 79 47
Leukocytosis 234 79 47
Background disease - - --
Cardiac surgery 8 (3.42) 29 (36.25) -
Heart failure 48 (20.51) 23 (28.75) 5 (10.64)
Transplanted (most kidney) 5 (2.14) 4 (5) -
Diabetic 96 (41.03) 16 (20) 29 (61.7)
COPD 24 (10.25) 5 (6.25) 7 (14.89)
Cancer, Surgery and other 53 (22.65) 3 (3.75) 6 (12.77)
Total 234 80 47
Table 2. Pneumonia Patient Characteristics.
* Patients who had more than one of these back ground disease, was grouped in one category. 
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cycling program was 95°C for 10 min and then 35 cycles 
of 10s at 95°C (denaturation) followed by 45s at 60°C 
with fluorescent collection (annealing and extension). 
Every sample was run in duplicate and the mean was 
reported. The efficacy of PCR (E) was calculated using 
the slope of standard curve in the equation: E = 10 (-1/
slope) -1 as described by Pfaffl (18). Comparisons of 
culture and real time PCR were performed by using 
Cohen´s Kappa test. The SPSS 13.0 software program 
was used for statistical analysis of the data. 
ReSULTS
Culture and characterization of isolates. Of 
361 clinical specimens, 38 yielded Acinetobacter in 
culture. The  Gram-negative non-motile coccobacilli 
that grew at 37 and 44°C were identified as A. 
baummanii if they were negative in oxidase and 
DNase tests but positive for decarboxylation of 
lysine, production of Xylosidase (by ONPX disk) 
and acidification of glucose and malate in OF media. 
The identity of all 38 isolates were re-confirmed by 
PCR based on the presence of blaox-51 as this gene 
previously was proved to be specific for identification 
of Iranian strains of A. baumanni (12). The results of 
bacteriology for 274 specimens were also positive 
for P. aeroginosa (n = 58), E. coli (n = 20), K. 
pneumonia (n = 26) and others. Staphylococcus spp. 
(n = 67) and other Gram positive cocci (n = 65) and 
the yeasts (n = 17) grew from the clinical specimens 
too (Table 3). Poly-microbial growth was observed 
in 235 specimens (65.71%) including those yielding 
more than 2 different bacteria and yeast in culture. 
Counting of A. baumannii colonies demonstrated the 
existence of less than 500 to more than 105 CFU/ml in 
positive cultures (Table 3). 
Five VAP patients infected with A. baumannii 
expired. In one of them the isolated A. baumannii 
showed PDR phenotype. Similarly, a lung transplanted 
patient who had polymicrobial infection was also 
infected with a PDR strain. However, in this patient 
as well as 6 other expired VAP cases Staphylococcus 
aureus was the main cause of death. Overall, 19 cases 
with VAP (23.75%) were expired. On the other hand, 
A. baumannii was the main cause of deaths (n = 4) 
in patients with HAP. Of 234 patients with HAP, 22 
(9.40 %) were expired. 
Clinical finding. Infiltration of lung (chest X-ray) 
was included as a criterion for hospital admission. All 
patients infected with A. baumannii had temperature 
body more than 38.5°C and leukocytosis. A lung 
transplanted patient had body temperature lower than 
36°C and leukopenia (less than 4000). Gram staining 
of direct smear in specimens showed more than 12-14 
White blood cells (WBC) per oil-high power field.
 
Culture quantification and Real time pCR. 
All specimens were cultured on Muller Hinton agar 
(10cm diameter plate) and semi-quantified. Real time 
PCR detected 38 samples as being positive for A. 
baumannii in culture and counted 790 and 3936 cfu/
ml in 2 specimens from HAP patients which showed 
less than 104cfu/ml in culture. This technique counted 
less CFUs than culture from CAP specimens (Table 3).
Standard curve of duplicated every dilution had 
slope -3.39 ±  0.1 and R2  > 0.99 with SD 0.1. Efficacy 
of PCR test was 97.25 % (E = 10 (-1/slope)-1) (18). 
Results of real time PCR and quantification of 
every sample are shown in Table 3. The sensitivity, 
specificity, and predictive values were 100%. 
Amplification of target genes from A. baumannii in 
serial dilutions ranged from 109 CFU /ml to 102 CFU 
/ml and showed that the technique can detect every 
calculated tube count with SD < 1%. The results were 
performed in duplicate. There was agreement between 
the results of culture and real-time PCR such that 
Cohen´s Kappa value was 1.0 (SD 0.00, p < 0.001). 
DISCUSSION 
Acinetobacter baumannii is the second most 
commonly isolated non-fermenting bacteria in 
healthcare associated infection and third infective 
organism at ICUs causing mortality rates of 26-68% 
(1, 19). This organism which has been nominated 
as the “bad bug” (20, 21), possesses intrinsic and 
acquired mechanisms of resistance to various classes 
of antibiotics (5). The multi-drug resistant (MDR) 
and pan-drug resistant (PDR) A. baumannii has also 
been described as a “very successful” pathogen  for 
escaping from every human challenge (6, 7, 20). 
Rapid detection of A. baumannii from patients with 
HAP or VAP and severe pneumonia is critical because 
A. baumannii may rapidly become resistant and life 
threatening (1). To accurately diagnose pneumonia and 
consequently prevent misuse or overuse of antibiotics 
(7), microbiological methods including quantitative 
culture and susceptibility pattern of isolated 
organisms should be implemented in diagnosis and 
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patients ID CFU in Culture Copy numbers inRT-pCR1 poly microbial infection
L1 10,000 7.36E + 03 P. aeroginosa
L46 100,000 2.40E + 5 S. aureus
L51 100,000 2.41E + 05
L59 50,000 9.62E + 04 E. fecalis
L76 100,000 4.98E + 07 P. aeroginosa
L99 50,000 6.70E + 04
R9 50,000 2.37E + 04 E. coliK. pneumoniae
R19 100,000 2.61E + 07 E. fecalisS. epidermidis
R22 100,000 1.75E + 06
R25 50,000 7.20E + 05 P. aeroginosaE. fecalis
R27 100,000 2.90E + 05
R34 50,000 6.34E + 04 P. aeroginosa
R39 10,000 6.73E + 03
R45 100,000 3.21E + 05
E20 10,000 7.41E + 05
E30 50,000 2.81E + 06 S. epideremidis
E39 50,000 2.17E + 04 S. aureus
E43 10,000 1.24E + 04
E48 10,000 3.42E + 04 S. maltophiliaP. aeroginosa
E65 100,000 8.07E + 09 A. niger
E67 100,000 7.25E + 09
E70 5,000 8.97E + 03
E73 100,000 8.46E + 08 Candida spp.S. epidermidis
E74 10,000 2.31E + 04
E77 5,000 3.54E + 03 S. aureus
E87 50,000 8.21E + 04
E88 50,000 4.67E + 04
E89 100,000 9.02E + 10 S. epidermidis
E92 10,000 1.57E + 04 S. aureus
E95* < 500* 756 S. aureus
E97 100,000 5.98E + 08 Alcaligenes sp.
M3 < 5,000 3974
M11 100,000 4.29E + 07
M27 10,000 5. 15E + 04
M44 50,000 4.26E + 06 K. pneumoniae
M 68 100,000 1.46E + 09
M82 100,000 1.38E + 07 S. maltophila
CAP 10,000 7750
Table 3. Results of culture and real-time PCR for Acinetobacter baumannii detected from patients with pneumonia at Tehran Hospitals. 
1-Real time-PCR was run in duplicate.
*Antibiotic regimen was changed to polymyxin B before sampling.
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therapeutic policy (2, 22). Most efforts for detection 
and identification of A. baumannii are based on 
phenotypic characteristics of isolated organisms and 
this takes at least three days to yield results. On the 
other hand, early detection and adequate treatment 
within 6-36 hours is critical for ICU patients (23, 24, 
25). Conventional PCR is not as sensitive and specific 
as real-time PCR because of carry-over contamination 
and false positive and false negative results due to the 
nature of post common PCR detection methods.  In 
addition, it also takes more time. 
Real-time PCR is rapid and sensitive. It gives results 
with high specificity but not at expense of sensitivity 
and so it can be used routinely in many laboratories. 
Despite the importance of accumulating data about A. 
baumannii, rapid detection method of this bacterium 
was scarce (3). So, we designed a TaqMan-based 
real-time PCR assay for detection and quantification 
of A. baumannnii from clinical specimens using the 
blaoxa51 gene. This gene was first reported by Brown 
et al. (26) and later was found to be specific for A. 
baumannii (3, 12, 27). Knowing this background, 
we designed primers and TaqMan probe with 100% 
specificity for direct detection and quantification of A. 
baumannii from respiratory specimens. This new rapid 
technique was used in challenge with a variety of Gram 
positive and Gram negative bacteria that may be present 
in respiratory specimens. Sensitivity of primer probe 
was checked in serially diluted standard tubes. It could 
detect 200 cfu/ml of bacteria in samples.
Early appropriate antimicrobial therapy decreases 
mortality rates. It requires quantitative culture with 
threshold of 104 cfu/ml of BAL or 103 cfu/ml for 
protected brush specimens to differentiate infection 
from non-infectious but suspected patients according 
to ATS/IDSA guidelines (28). For specimens other 
than BAL (tracheal aspirate, sputum and throat 
swab), the quantification should be compared with 
clinical findings and chest infiltrates. In presence of 
symptoms, it is suggested that 104cfu/ml of bacteria 
is compatible with infection although sputum and 
tracheal aspiratyield more than 105cfu/ml bacteria 
in infection cases. Detection of A. baumannii at low 
numbers may be indicative of infection and antibiotic 
therapy can possibly be a reason in such cases. For 
example, two patients (E95 and M3 isolates) had lower 
than 104cfu/ml A. baumannii in their specimens (They 
were counted by real-time PCR, 795 and 3937 cfu/ml 
respectively). M3 was isolated from a transplant patient 
who was under antibiotic therapy and its specimen 
was quantified for monitoring and efficacy of therapy. 
The antibiotic regimen of the second patient (E95) had 
been changed in 24 hours before sampling. Fabregas 
et al. (1999) suggested that counting of 103-105cfu/ml 
in specimens from lung autopsy is compatible with 
pneumonia (29). Torres and El-Ebiary reviewed 23 
studies and reported threshold of colonization and 
infection of BAL specimens to be 104cfu/ml or lower 
(30). The results of our real-time PCR also suggest 
that the threshold for every sample from HAP and 
VAP should be considered as 104CFUs/ml. Based on 
the Iceberg model of A. baumannii colonization (3), 
and its potential for intrinsic and acquired resistance, 
we recommend appropriate therapy be initiated 
when real-time PCR detects even less than 103 cfu/
ml. A recent survey on 55,330 isolates in the USA 
demonstrated that A. baumannii becomes carbapenem 
resistant with faster growth when it is colonized in 
the respiratory tract (31). This finding supports our 
recommendation to start antimicrobial therapy when 
the bug has colonized the lower respiratory tract at 
lower numbers than threshold. Obviously, mechanical 
intubation and potential of introducing bacteria to 
the lower respiratory tract and expression of silent 
intrinsic resistance genes under antibiotic pressure may 
help faster spreading of resistant isolates. The prevalence 
of A. baumannii at Tehran hospitals (10.2%) was similar 
to Korea (9%) (24), but lower than India, Taiwan, 
Bahrain and Turkey (p < 0.001) (24) and polymicrobial 
infections were found in 13.3% of all specimens which 
is close to other studies (9). A. baumannii was found as 
the third bacterium after P. aeruginosa and S. aureus 
isolated from HAP and VAP cases, but a higher mortality 
in patients with VAP were associated with S. aureus and 
A. baumannii (7 and 6 cases, respectively). MDR and 
PDR isolates explosion of A. baumannii in medical 
care units is a global problem. To control this “very 
successful pathogen”, rapid detection is very important. 
Care should be taken in pneumonia cases with less than 
104 cfu/ml of A. baumannii. Otherwise, it can impose 
great costs to the public health. 
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